

*Cost Utilization Analysis of Inhaled Steroids
for Allergic Rhinitis Management*

This supplement to *The American Journal of Managed Care* contains information on the latest intranasal corticosteroids for allergic rhinitis. This supplement has been peer reviewed by an expert in the field.

Faculty

Leon Dupclay, Jr, PharmD, PhD

Manager
Health Economics and Outcomes Research
Aventis Pharmaceuticals
Bridgewater, New Jersey

Joseph Doyle, RPh, MBA

Senior Manager
Health Economics and Outcomes Research
Aventis Pharmaceuticals
Bridgewater, New Jersey

DISCLOSURE STATEMENT

It is the policy of *The American Journal of Managed Care* to have all faculty who participate in programs sponsored by corporate organizations disclose any real or apparent conflicts of interest.

These participants are employees of Aventis Pharmaceuticals:

- **Leon Dupclay, Jr, PharmD, PhD**
- **Joseph Doyle, RPh, MBA**

Signed disclosures are on file at the offices of *The American Journal of Managed Care*, Jamesburg, New Jersey.

*Cost Utilization Analysis of Inhaled Steroids
for Allergic Rhinitis Management*

This program is supported by an educational grant from **Aventis Pharmaceuticals Inc.**



The contents of this supplement may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.